Novo Nordisk latest outlook trim shows “quick momentum loss”
Novo Nordisk has cut its outlook for 2025 as lower expectations for glucagon-like peptide-1 receptor agonists (GLP-1RA) continue to hit …
Post
-
-
Agentic, deeply embedded AI constitutes the “next wave” of tech
Artificial intelligence (AI) has become a key buzzword in the pharmaceutical industry, with most, if not all, companies looking to …
-
Avant and SGAustria form JV to develop diabetes therapy
Avant Technologies and SGAustria have announced a joint venture (JV) and licence agreement to advance a therapy for diabetes using …
-
The latest regulatory updates affecting parenteral packaging
Regulations are the cornerstone of the pharmaceutical industry, with parenteral packaging often an area of scrutiny due to its importance …
-
Innovation meets convenience: Redefining lyophilized drug delivery for patients
Over the past few decades, the pharmaceutical industry has seen a steady shift toward parenteral self-administration and home-based care. As …
-
Sri Lanka’s drug pricing reform: balancing affordability with sustainability
Ensuring fair and transparent pharmaceutical pricing was a key promise of Sri Lanka’s ruling government’s election manifesto, and that promise …
-
Novo Nordisk and Pfizer’s bidding war for Metsera escalates despite legal threats
Novo Nordisk has raised its offer to buy out obesity biotech Metsera to $10bn as a bidding war with Pfizer …
-
MSD secures $700m for broad-cancer ADC asset
Antibody-drug conjugates (ADCs) continue to be à la mode in the oncology sector, with Merck & Co (MSD) tying up …
-
AmacaThera and Pacira sign agreement for AMT-143
AmacaThera has entered into an exclusive worldwide licensing agreement with Pacira BioSciences for up to $230m for AMT-143, an investigational …
-
Boehringer and CDR-Life announce licensing deal for autoimmune disease therapy
Boehringer Ingelheim and CDR-Life have announced a worldwide licencing agreement for the development of CDR111, an antibody-based molecule targeting autoimmune conditions. CDR111 …
-
FDA halts uniQure’s plans for Huntington’s disease gene therapy
The path to approval for uniQure’s gene therapy candidate for Huntington’s disease is in doubt as the US Food and …
-
Tidmarsh’s FDA exit marks latest high-profile jockeying at US agencies
George Tidmarsh has resigned from the US Food and Drug Administration (FDA), becoming the latest in a long line of …
-
Top 20 biopharma companies Q3 2025 market cap up 4% despite headwinds
The top 20 global biopharmaceutical companies experienced mixed performances in their individual market capitalisations in the third quarter (Q3) of …
-
ViiV Healthcare launches ‘Risk to Reasons’ initiative in the UK to empower women to take control of their HIV prevention choices
While surveillance data from 2024 shows an encouraging reduction in HIV transmissions1, more needs to be done to meet the …
-
Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn
Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for $48.7bn. One of America’s largest consumer health …
